To extend these findings and investigate the clinical relevance of PSAT1 in EGFR-mutant lung cancer, we analyzed microarray datasets from patients with EGFR-mutant lung tumors for a comparative expression analysis and correlation with clinical outcomes. This evidence concerns the gene PSAT1 and lung carcinoma.